Dr. Postow Discusses Side Effects with Combinations in Melanoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,